Are there any special precautions for patients with diabetes mellitus?

Apelix, this drug has shown unique efficacy in the treatment of hormone receptor-positive, human epidermal growth factor receptor2-negative advanced or metastatic breast cancer carrying PIK3CA gene mutations. However, for patients with diabetes, there are some special precautions that need to be taken when using Apelvis to ensure the safety of the treatment.

First of all, Apelvis may cause the side effect of raising blood sugar. In clinical trials, severe hyperglycemia, including ketoacidosis, has been reported in patients treated with Apelvis. Of particular note, the safety of Apelvis has not been clearly established in patients with type 1 or uncontrolled type 2 diabetes.

Therefore, for patients with diabetes, before starting treatment with Apelvis, doctors should first test the patient's fasting blood glucose (FPG) and HbA1c levels to assess the patient's blood sugar control. At the same time, depending on the patient's clinical condition, doctors may need to optimize the patient's hypoglycemic treatment plan to ensure that the patient's blood sugar level can be effectively controlled during the use of Apelvis.

During treatment, doctors also need to regularly monitor the patient's blood sugar levels to detect and deal with any potential elevated blood sugar problems in a timely manner. If a patient develops severe hyperglycemia while taking Apelvis, doctors may consider suspending, reducing the dose of the drug, or discontinuing Apelvis to ensure the patient's safety.

Overall, while Apelvis provides a new treatment option for patients with certain types of breast cancer, patients with diabetes need to pay special attention to blood sugar control and monitoring when using this drug. Through reasonable blood sugar management and close monitoring by doctors, diabetic patients can effectively use Apelvis for treatment while ensuring safety.